Lenacapavir HIV Prevention: Gilead’s Stra...

By João L. Carapinha

July 10, 2025

Gilead Sciences has finalized a strategic partnership with the Global Fund. The agreement aims to supply lenacapavir HIV prevention, a twice-yearly inject...
Revolutionizing Pediatric Care: Approval of Malaria Medicine for Newborns
Talquetamab Multiple Myeloma: Impact, Evidence, and Policy Considerations
Masitinib Prostate Cancer Trial Gains FDA and EMA Approval for Phase 3 Study
BEBT-908 DLBCL Treatment: A Milestone Approval for a First-in-Class Dual Inhi...
AI Clinician in Pediatric ICU: A Review and HEOR Perspective
Cell Therapy for Type 1 Diabetes: Vertex Trial Results and Market Potential
FDA Approval and Access Strategy for Lenacapavir (Yeztugo) Long-Acting HIV Pr...
NICE Rejects Donanemab: Treatment Cost-Effectiveness
Efficacy of Ultomiris Pediatric TMA Treatment
How Gene-Editing Therapies Are Revolutionizing ASCVD Treatment and Market Tra...
PCV20 Reimbursement Guidelines: Analysis of Dutch Advisory Council Recommenda...
NICE Approves Transformative Multiple Myeloma Treatment